Calcipotriol with betamethasone
Brand names: Dovobet, Enstilar, Wynzora
A topical fixed-combination of the vitamin D analogue calcipotriol with the potent corticosteroid betamethasone, used once daily for plaque psoriasis affecting the trunk, limbs and scalp.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Calcipotriol acts on the vitamin D receptor to regulate excessive keratinocyte proliferation and differentiation, while betamethasone provides anti-inflammatory and immunosuppressive effects, giving complementary plaque clearance.
Prescribing in practice
- Restrict the weekly quantity and the treated surface area, since excessive calcipotriol absorption can cause hypercalcaemia and the potent corticosteroid adds risks of skin atrophy and adrenal suppression.
- Avoid the face, flexures, broken skin and occlusion.
- Not indicated for guttate, erythrodermic or generalised pustular psoriasis.
Monitoring
Reassess the plaques periodically and stay within the recommended maximum weekly amount to limit hypercalcaemia and corticosteroid effects.
Counselling the patient
- Use once daily on the affected patches only, avoiding healthy skin and the face.
- Wash your hands after applying and do not use more than the weekly limit advised.
Evidence & guidelines
NICE recommends a combined potent corticosteroid and vitamin D analogue as first-line topical treatment for plaque psoriasis on the body.
Reference: NICE CG153; BAD; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD